The Semaglutide Surge: How a diabetes therapy sparked India’s weight loss wave
As demand for GLP-1 therapies explodes, India’s drug regulator moves to curb advertising amid rising concerns over misuse, access, and long-term impact
As demand for GLP-1 therapies explodes, India’s drug regulator moves to curb advertising amid rising concerns over misuse, access, and long-term impact
Final approval for diabetes and heart-failure drug opens access to a $10.5 billion US market opportunity, with shared exclusivity benefits.
Searches for diabetes, heart conditions, and metabolism-related risks are rising sharply, with Tier 2 cities outpacing metros in specialist consultations
Participants also experienced a VR-enabled learning environment designed to support clinical skill development in controlled, repeatable, and risk-free settings
Former Interim CEO takes charge to drive strategic growth, strengthen clinical excellence, and advance patient-centric oncology innovation
Veteran HR leader comes with over two decades of experience to spearhead talent strategy, leadership development, and culture transformation
Move aligns global biologics identity under the Biocon Biologics brand
As part of the deal, Red Nucleus also gains indirect ownership of the company’s Indian arm
Samsung Biologics will continue supplying products previously manufactured at the site to GSK
Researchers say simple blood-test and echocardiography pathway could reshape diabetes-related cardiovascular care
Subscribe To Our Newsletter & Stay Updated